Sandoz has secured FDA approval for Abbreviated New Drug Application (ANDA) ANDA076873 on December 14, 2004, which will allow the company to immediately enter the market with a generic version of the respective pharmaceutical product. This regulatory clearance positions Sandoz to capture market share amidst patent expirations and intensifies competitive pressures on branded manufacturers.